Medtronic plc to acquire CathWorks for up to $585M, bringing AI FFRangio into cath labs
- Medtronic to acquire CathWorks for up to $585M to expand its cardiovascular and interventional cardiology pipeline. • Medtronic is acquiring FFRangio, an AI system that maps coronary physiology from routine angiograms. • Medtronic plans global rollout and integration to disrupt wire‑based FFR and improve cath‑lab decision‑making.
Medtronic to acquire CathWorks, pushing AI diagnostics into cath labs
GALWAY, Ireland, Feb. 3 (Reuters) — Medtronic plc announces it will exercise its option to acquire privately held CathWorks, advancing a relationship that began with a 2022 strategic partnership and co‑promotion agreement for the FFRangio® System. The deal is valued at up to $585 million, plus potential undisclosed post‑close earn‑out payments, and follows commercial availability of the technology in the United States, Europe and Japan. Medtronic frames the move as part of a broader effort to expand its cardiovascular pipeline and strengthen its interventional cardiology offerings.
AI‑driven physiology mapping aims to change cath lab workflows
Medtronic says the acquisition centers on the FFRangio System, which uses artificial intelligence and advanced computational science to produce a comprehensive physiological assessment of the entire coronary tree from routine coronary angiograms. The company highlights that FFRangio addresses limitations of wire‑based fractional flow reserve — an invasive measurement that needs pressure wires and pharmacologic hyperemia and yields values at a single location. Jason Weidman, senior vice president and president of Medtronic’s Coronary & Renal Denervation business, says co‑promotion experience shows the FFRangio system can disrupt traditional wire‑based FFR by leveraging data and AI to provide real‑time information that supports individualized patient pathways from diagnosis to treatment.
Medtronic positions the technology as a way to transform decision making in the cath lab by delivering broader physiologic mapping that informs revascularization choices, with the goal of avoiding unnecessary percutaneous coronary interventions and improving outcomes. The company points to clinical studies that demonstrate FFRangio’s diagnostic accuracy and “promising” clinical outcomes, asserting that integrating less invasive, data‑driven diagnostics into its therapeutic portfolio will accelerate innovation in cath lab workflows and scale access across hospitals and health systems.
Commercial footprint and next steps
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

